Article

Combined use of rapid D-Dimer testing and estimation of clinical probability in the diagnosis of deep vein thrombosis: systematic review. BMJ

Division of General Medicine, University of California at Davis, Patient Support Services Building, Suite 2400, Sacramento, California 95817, USA.
BMJ (online) (Impact Factor: 16.38). 11/2004; 329(7470):821. DOI: 10.1136/bmj.38226.719803.EB
Source: PubMed

ABSTRACT To summarise the evidence supporting the use of rapid d-dimer testing combined with estimation of clinical probability to exclude the diagnosis of deep venous thrombosis among outpatients.
Medline (June 1993 to December 2003), the Database of Abstracts and Reviews (DARE), and reference lists of studies in English.
We selected 12 studies from among 84 reviewed. The selected studies included more than 5000 patients and used a rapid D-dimer assay and explicit criteria to classify cases as having low, intermediate, or high clinical probability of deep vein thrombosis of the lower extremity among consecutive outpatients.
Diagnosis required objective confirmation, and untreated patients had to have at least three months of follow up. The outcome was objectively documented venous thromboembolism. Two authors independently abstracted data by using a data collection form.
When the less sensitive SimpliRED D-dimer assay was used the three month incidence of venous thromboembolism was 0.5% (95% confidence interval 0.07% to 1.1%) among patients with a low clinical probability of deep vein thrombosis and normal D-dimer concentrations. When a highly sensitive D-dimer assay was used, the three month incidence of venous thromboembolism was 0.4% (0.04% to 1.1%) among outpatients with low or moderate clinical probability of deep vein thrombosis and a normal D-dimer concentration.
The combination of low clinical probability for deep vein thrombosis and a normal result from the SimpliRED D-dimer test safely excludes a diagnosis of acute venous thrombosis A normal result from a highly sensitive D-dimer test effectively rules out deep vein thrombosis among patients classified as having either low or moderate clinical probability of deep vein thrombosis.

Download full-text

Full-text

Available from: Richard L Kravitz, Aug 18, 2014
0 Followers
 · 
64 Views
  • Source
    • "anisms of vascular injury , underlying hereditary disorders , and proposed risk factors adds a body of new information for consideration . This knowledge may direct both the clinical reasoning process and future research into pre - treatment cervical risk assessment . This may direct research toward the model used in suspected thrombo - embolism ( Fancher et al . , 2004 ) , a condition which mirrors VA and ICA dissection in its complex patho - genesis and level of difficulty to diagnose or predict accurately ."
    [Show abstract] [Hide abstract]
    ABSTRACT: An abundance of literature has attempted to provide insight into the association between cervical spine manual therapy and cervical artery dysfunction leading to cerebral ischaemic events. Additionally, specific guidelines have been developed to assist manual therapists in clinical decision-making. Despite this, there remains a lack of agreement within the profession on many issues. This paper presents a critical, re-examination of relevant literature with the aim of providing a contemporary, evidence-informed review of key areas regarding the neurovascular risks of cervical spine manual therapy. From a consideration of case reviews and surveys, haemodynamic principles, and blood flow studies, the authors suggest that: (1) it is currently impossible to meaningfully estimate the size of the risk of post-treatment complications; (2) existing testing procedures have limited clinical utility; and (3) a consideration of the association between pre-existing vascular risk factors, combined with a system based approach to cervical arterial haemodynamics (inclusive of the carotid system), may assist manual therapists in identifying at-risk patients.
    Manual therapy 09/2008; 13(4):278-88. DOI:10.1016/j.math.2007.10.006 · 1.76 Impact Factor
  • Source
    • "The prevalence of VTE is 5–6% in patients with a low clinical probability according to the Wells score and 19–24% in those with an intermediate probability [12]. The incidence of VTE in patients with a low pre-test probability (PTP) varies between 0.6% and 1.8% [4] [7]. The reliability of the PTP score also depends on the personal skills of the user [12] [13], which may reduce its usefulness. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients presenting with symptoms suggestive of venous thromboembolism (VTE), i.e., deep vein thrombosis (DVT) and pulmonary embolism (PE), are common at the emergency departments. However, of those, only 15-25% actually have the disease. The aims of this study were to determine (1) if low pre-test probability (PTP) using the Wells score, together with a normal D-dimer, safely excludes VTE in outpatients and (2) if a follow-up D-dimer adds extra information. Patients (n=151, 68% women) with suspected VTE, a PTP below 1.5, and a D-dimer test (TinaQuant) below 0.5 mg/L were included in the study and underwent no further diagnostic investigations. Patients (n=177, 54% women) with D-dimer levels of 0.5 mg/L or higher or a PTP of 1.5 or higher were excluded. A follow-up D-dimer test was conducted 3-7 days after the initial hospital visit and further diagnostic investigations were made if test results were abnormal. Patients were studied for 3 months. A follow-up D-dimer test was conducted in 101/151 cases (67%), 13/101 of which revealed elevated D-dimer levels. None of these 13 patients had persistent symptoms or was diagnosed with VTE. All 151 patients were contacted after 3 months; none of them had clinical signs of VTE. Of the 177 patients excluded, 45 (25%) were diagnosed with VTE. Of the 176/328 (151+177) patients with normal D-dimer levels, only 1 had VTE (<0.01%). A normal PTP using the Wells score and a normal D-dimer safely excludes VTE at the emergency department. A follow-up D-dimer test adds no further information.
    European Journal of Internal Medicine 07/2008; 19(4):285-8. DOI:10.1016/j.ejim.2007.08.007 · 2.30 Impact Factor
  • Source
    • "Designed to target specific epitopes in tissues, these agents are beginning to enter clinical trials for cardiovascular applications. There are numerous proteins whose presence has been implicated as a marker for thrombosis [94] [95] [96] [97] [98] [99]. These investigations have driven a search for a panel of diagnostic markers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanomedicine is a global business enterprise. Industry and governments clearly are beginning to envision nanomedicine's enormous potential. A clear definition of nanotechnology is an issue that requires urgent attention. This problem exists because nanotechnology represents a cluster of technologies, each of which may have different characteristics and applications. Although numerous novel nanomedicine-related applications are under development or nearing commercialization, the process of converting basic research in nanomedicine into commercially viable products will be long and difficult. Although realization of the full potential of nanomedicine may be years or decades away, recent advances in nanotechnology-related drug delivery, diagnosis, and drug development are beginning to change the landscape of medicine. Site-specific targeted drug delivery and personalized medicine are just a few concepts that are on the horizon.
    Medical Clinics of North America 10/2007; 91(5):805-43. DOI:10.1016/j.mcna.2007.05.009 · 2.80 Impact Factor
Show more